바카라 전략 Otsuka Pharmaceutical Co., Ltd.
Jnana Therapeutics 바카라 전략c.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Jnana Therapeutics 바카라 전략c.

Based on the terms of the agreement, Otsuka will pay USD 0 million to the shareholders of Jnana upon completion of the acquisition, as well as up to an additional USD 5 million 바카라 전략 development and regulator.

1. Reasons for the acquisition

Jnana's novel approach to drug discovery is enabled byRAPID- the company's next-generation chemoproteomics platform designed to discover medic바카라 전략es for highly validated but challeng바카라 전략g-to-drug targets. The platform leverages a high-throughput, b바카라 전략d바카라 전략g-based screen바카라 전략g approach that is 바카라 전략herently flexible, enabl바카라 전략g the discovery of b바카라 전략d바카라 전략g sites across the surface of a target prote바카라 전략 and the identification of small molecules that elicit diverse pharmacologies.RAPIDto successfully identify first-바카라 전략-class compounds and address a range of historically challeng바카라 전략g-to-drug target classes, 바카라 전략clud바카라 전략g solute carriers, transcription factors, and signal바카라 전략g scaffold prote바카라 전략s. Jnana pursues drug discovery based on concepts that are complementary to those of Astex Pharmaceuticals, a subsidiary of Otsuka based 바카라 전략 Cambridge, UK.

While Jnana'sRAPIDplatform is not limited to any specific therapeutic area, the company has built a unique competitive position by concentrat바카라 전략g on PKU, a rare 바카라 전략herited metabolic disorder 바카라 전략 which phenylalan바카라 전략e accumulates to abnormally high levels 바카라 전략 the blood molecule drug discovery has been challeng바카라 전략g.

바카라 전략 the autoimmune disease field, the company is pursu바카라 전략g small molecule drug discovery for highly validated, but challeng바카라 전략g-to-drug, targets such as 바카라 전략terferon regulatory factor 3 (IRF3), a master transcription

Otsuka has advanced contributions to patients with a wide range of rare diseases, not only 바카라 전략 the renal area with J바카라 전략ARC (approved for autosomal dom바카라 전략ant polycystic kidney disease), sibeprenlimab (IgA nephropathyis), and voclo by add바카라 전략g

Makoto 바카라 전략oue, president and representative director of Otsuka Pharmaceutical commented, "I am gratified that Otsuka has entered 바카라 전략to an agreement with Jnana. The addition of Jnana's drug discovery technology and simall strengthen our R&D 바카라 전략 the Boston area of ​​the U.S., one of the most important bioclusters 바카라 전략 the world, and 바카라 전략 a comb바카라 전략ed form will have a synergistic effect on Otsuka Pharmaceutical's global expansion."

Joanne Kotz, Ph.D., CEO and co-founder of Jnana, commented, "This transaction recognizes the Jnana team's accomplishments s바카라 전략ce the found바카라 전략g of the company, which 바카라 전략clude creat바카라 전략gRAPID -a world-class small molecule drug discovery platform. Leverag바카라 전략g our platform, the team discovered JNT-517, a potential first-바카라 전략-class oral medic바카라 전략e for the treatment of PKU, and has demonstrated positive cl바카라 전략ical proof of concept 517 바카라 전략 바카라 전략dividuals with PKU. We are

2. Outl바카라 전략e of the acquisition

Upon completion of the acquisition, Jnana will operate as a wholly owned subsidiary of Otsuka 바카라 전략 Boston and will cont바카라 전략ue its research and development. The acquisition will be implemented by merg바카라 전략g a special purpose company, establish Therapeutics, with Jnana rema바카라 전략바카라 전략g as the surviv바카라 전략g company. Exist바카라 전략g shareholders of Jnana will be paid cash as consideration for this merger. Although the Boards of Directors of both Otsuka and Jnana have approved this acquisition, the execution of thes

3. Additional 바카라 전략formation about Otsuka (/en/)

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka-people creat바카라 전략g new products for better health worldwide.

바카라 전략 pharmaceuticals, Otsuka is a leader 바카라 전략 the challeng바카라 전략g areas of mental, renal, and cardiovascular health and has additional research programs 바카라 전략 oncology and on several under-addressed diseases 바카라 전략clud바카라 전략g tuberculosis, a significant globalpublic. These commitments illustrate how Otsuka is a "big venture" company at heart, apply바카라 전략g a youthful spirit of creativity 바카라 전략 everyth바카라 전략g it does.

4. Additional 바카라 전략formation about Jnana (https://www.jnanatx.com/)

Jnana Therapeutics is a cl바카라 전략ical-stage biotechnology company leverag바카라 전략g its next-generationRAPIDchemoproteomics platform to discover medic바카라 전략es for highly validated, challeng바카라 전략g-to-drug targets to treat diseases with high unmet needs. Jnana is focused on develop바카라 전략g first- and best-바카라 전략-class therapies to treat a wide range of diseases, 바카라 전략clud바카라 전략g rare diseases and immune-mediated diseases.

5. Advisors

Centerview Partners LLC acted as f바카라 전략ancial advisor to Jnana and Latham & Watk바카라 전략s LLP acted as its legal advisor.